Magid Abou‐Gharbia

Pharmacological Stratification of Public Bioactivity Databases: A Reusable, OECD-Anchored Curation and Benchmarking Framework Demonstrated for Opioid Receptors

Manal Nael, Laxman M. Alakonda, Abhik Ghosh, Sara Jane Ward et autres

Abstract Public bioactivity databases are heterogeneous not only in measurement type, where binding affinities and functional potencies are reported on different scales, but in pharmacology: the same compound and target can carry agonist, antagonist, or inhibitor records measured through binding displacement, cAMP, …

us, Égypte (code pays fourni par la source)

Time to Approval of Drugs in FDA Expedited Programs, 2020–2024

Nicole Damour, Magid Abou‐Gharbia, Magid Abou-Gharbia, David Lebo

Abstract US Food and Drug Administration (USFDA) offers four Expedited Programs (EPs): Accelerated Approval (AA), Fast Track designation (FT), Breakthrough Therapy designation (BT) and Priority Review (PR). As Gadekar recently presented, understanding the frequency of EP assignment and application types is useful …

us (code pays fourni par la source)

Supplementary Table 2 from Parkin Induces Ubiquitination and Large Extracellular Vesicle Release of HMGB1 to Activate Antitumor Immunity

Minjeong Yeon, Michela Perego, Khaled M. Elokely, Magid Abou‐Gharbia et autres

Antibodies used for flow cytometry experiments in these studies.

Supplementary Figure 4 from Parkin Induces Ubiquitination and Large Extracellular Vesicle Release of HMGB1 to Activate Antitumor Immunity

Minjeong Yeon, Michela Perego, Khaled M. Elokely, Magid Abou‐Gharbia et autres

Characterization of PRKN-HMGB1 large extracellular vesicles.

Supplementary Figure 5 from Parkin Induces Ubiquitination and Large Extracellular Vesicle Release of HMGB1 to Activate Antitumor Immunity

Minjeong Yeon, Michela Perego, Khaled M. Elokely, Magid Abou‐Gharbia et autres

PRKN-HMGB1 stimulation of IFN signaling.

Supplementary Figure 1 from Parkin Induces Ubiquitination and Large Extracellular Vesicle Release of HMGB1 to Activate Antitumor Immunity

Minjeong Yeon, Michela Perego, Khaled M. Elokely, Magid Abou‐Gharbia et autres

PRKN ubiquitination of HMGB proteins.

Supplementary Table 4 from Parkin Induces Ubiquitination and Large Extracellular Vesicle Release of HMGB1 to Activate Antitumor Immunity

Minjeong Yeon, Michela Perego, Khaled M. Elokely, Magid Abou‐Gharbia et autres

Primer sequences used for PCR amplification experiments.

Supplementary Figure 2 from Parkin Induces Ubiquitination and Large Extracellular Vesicle Release of HMGB1 to Activate Antitumor Immunity

Minjeong Yeon, Michela Perego, Khaled M. Elokely, Magid Abou‐Gharbia et autres

PRKN regulation of autophagy.

Supplementary Figure 7 from Parkin Induces Ubiquitination and Large Extracellular Vesicle Release of HMGB1 to Activate Antitumor Immunity

Minjeong Yeon, Michela Perego, Khaled M. Elokely, Magid Abou‐Gharbia et autres

PRKN-HMGB1 antitumor immunity.

Supplementary Figure 3 from Parkin Induces Ubiquitination and Large Extracellular Vesicle Release of HMGB1 to Activate Antitumor Immunity

Minjeong Yeon, Michela Perego, Khaled M. Elokely, Magid Abou‐Gharbia et autres

Immuno-gold labeling of HMGB1-associated membranous structures.

Supplementary Figure 6 from Parkin Induces Ubiquitination and Large Extracellular Vesicle Release of HMGB1 to Activate Antitumor Immunity

Minjeong Yeon, Michela Perego, Khaled M. Elokely, Magid Abou‐Gharbia et autres

Requirement of PRKN-HMGB1-induced IFN signaling for CD8 T cell activation.

Supplementary Table 3 from Parkin Induces Ubiquitination and Large Extracellular Vesicle Release of HMGB1 to Activate Antitumor Immunity

Minjeong Yeon, Michela Perego, Khaled M. Elokely, Magid Abou‐Gharbia et autres

siRNA sequences used for gene silencing in these experiments.